Back
The immune system and cancer evasion strategies: therapeutic concepts.
Journal article

The immune system and cancer evasion strategies: therapeutic concepts.

  • Muenst S Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Läubli H Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Soysal SD Department of Surgery, University Hospital Basel, Basel, Switzerland.
  • Zippelius A Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Tzankov A Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Hoeller S Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Show more…
  • 2016-01-11
Published in:
  • Journal of internal medicine. - 2016
immune checkpoints
immune regulators
immunoediting
immunosurveillance
siglecs
Animals
Dendritic Cells
Humans
Immunotherapy
Killer Cells, Natural
Lung Neoplasms
Macrophages
Melanoma
Neoplasms
T-Lymphocytes
English The complicated interplay between cancer and the host immune system has been studied for decades. New insights into the human immune system as well as the mechanisms by which tumours evade immune control have led to the new and innovative therapeutic strategies that are considered amongst the medical breakthroughs of the last few years. Here, we will review the current understanding of cancer immunology in general, including immune surveillance and immunoediting, with a detailed look at immune cells (T cells, B cells, natural killer cells, macrophages and dendritic cells), immune checkpoints and regulators, sialic acid-binding immunoglobulin-like lectins (Siglecs) and other mechanisms. We will also present examples of new immune therapies able to reverse immune evasion strategies of tumour cells. Finally, we will focus on therapies that are already used in daily oncological practice such as the blockade of immune checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) in patients with metastatic melanoma or advanced lung cancer, or therapies currently being tested in clinical trials such as adoptive T-cell transfer.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/194748
Statistics
Document views: 8 File downloads: